Conference Coverage

VIDEO: Study of hs-cTnT in chest pain intriguing, but flawed


 

AT ACC 14

WASHINGTON – The lack of detectable high-sensitivity cardiac troponin T in patients presenting with chest pain may be a marker of minimal risk of myocardial infarction within 30 days, according to Dr. Nadia Bandstein of the department of medicine at the Karolinska Institute, Solna, Sweden.

She and her colleagues looked at data from all emergency department visits for chest pain during 2010-2012 in Sweden. They found that the negative predictive value of myocardial infarction at 30 days for patients reporting with an hs-cTnT level of less than 5 ng/L, in addition to an ECG showing no blood flow-related damage, was 99.8%. That negative predictive value for death, meaning the patients are not at risk, was 100%.

Discussant Dr. Allan Jaffe of the Mayo Clinic in Rochester, Minn., said in an interview that although these findings are promising, the documentation in this study is not sufficient to use in clinical practice to let patients with these characteristics leave the emergency department.

*Update (3/31/14): This video has been updated.

mzoler@frontlinemedcom.com

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Persistent depression doubled coronary heart disease risk
MDedge Cardiology
Recent data support preventive multivessel PCI in STEMI patients
MDedge Cardiology
FDA reviewers support approval of platelet inhibitor cangrelor for PCI indication
MDedge Cardiology
NSAID makers argue against new warnings on CV risks
MDedge Cardiology
No new cardiovascular warnings needed for NSAIDs say FDA advisers
MDedge Cardiology
FDA panel votes against cangrelor approval for PCI, bridge indications
MDedge Cardiology
No ACS approvals for rivaroxaban, Janssen announces
MDedge Cardiology
USPSTF: Insufficient evidence to judge vitamin supplements
MDedge Cardiology
RAS blocker prescriptions still lag for ACS patients
MDedge Cardiology
'Revolutionary' LDL lowering shown in evolocumab phase III trials
MDedge Cardiology